XNCR(Xencor, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $275.11M | $164.58M | $174.62M | $110.49M | $125.58M |
| 毛利润 | — | — | — | — | — |
| 营业利润 | $43.77M | −$82.47M | −$132.36M | −$178.41M | −$177.50M |
| 净利润 | $82.63M | −$55.18M | −$133.13M | −$232.62M | −$91.92M |
| 经营现金流 | −$16.85M | $24.48M | −$77.93M | −$202.19M | −$135.12M |
| 自由现金流 | −$30.15M | −$14.01M | −$96.37M | −$208.28M | −$138.27M |
| 摊薄每股收益 | $1.37 | $-0.93 | $-2.20 | $-3.58 | $-1.24 |